Prevalence of pneumococcal bacteremia among children <36 months of age presenting with moderate fever to pediatric emergency rooms of the Metropolitan Region (Santiago), Chile

Human Vaccines

Volumn 2, Issue 3, 2006, Pages 129-133

  Lagos, Rosanna M ^a,b   Muñoz, Alma E ^a   Levine, Myron M ^c  

^a Centro para Vacunas en Desarrollo Chile   (Chile)

^b HOSPITAL ROBERTO DEL RÍO   (Chile)

^c University of Maryland School of Medicine Center for Vaccine Development   (United States)

Author keywords

Bacteremia; Children; Disease burden; Epidemiology; Fever; Infants; Pneumococcus; Streptococcus pneumoniae; Vaccine

Indexed keywords

AMBULATORY CARE; ARTICLE; BACTEREMIA; BLOOD CULTURE; CHILE; CONTROLLED STUDY; EMERGENCY WARD; FEVER; HUMAN; INCIDENCE; INFANT; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PEDIATRIC WARD; PRESCHOOL CHILD; PREVALENCE; PUBLIC HOSPITAL; STREPTOCOCCUS PNEUMONIAE;

EID: 33748069162     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.2894     Document Type: Article

References (22)

1. Black S, Shinefield H, Fireman B, Lewis E, Ray P, Hansen JR, Elvin L, Ensor KM, Hackell J, Siber G, Malinoski F, Madore D, Chang I, Kohberger R, Watson W, Austrian R, Edwards K. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J 2000; 19:187-95.
2. Klugman KP, Madhi SA, Huebner RE, Kohberger R, Mbelle N, Pierce N. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med 2003; 349:1341-8.
3. O'Brien KL, Moulton LH, Reid R, Weatherholtz R, Oski J, Brown L, Kumar G, Parkinson A, Hu D, Hackell J, Chang I, Kohberger R, Siber G, Santosham M. Efficacy and safety of seven-valent conjugate pneumococcal vaccine in American Indian children: Group randomised trial. Lancet 2003; 362:355-61.
4. Cutts FT, Zaman SMA, Enwere G, Jaffar S, Levine OS, Okoko JB, Oluwalana C, Vaughan A, Obaro SK, Leach A, McAdam KP, Biney E, Saaka M, Onwuchekwa U, Yallop F, Pierce NF, Greenwood BM, Adegbola RA, Gambian Pneumococcal Vaccine Trial Group. Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: Randomised, double-blind, placebo-controlled trial. Lancet 2005; 1139-46.
5. Black SB, Shinefield HR, Hansen J, Elvin L, Laufer D, Malinoski F. Postlicensure evaluation of the effectiveness of seven valent pneumococcal conjugate vaccine. Pediatr Infect Dis J 2001; 20:1105-7.
6. Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, Lynfield R, Reingold A, Cieslak PR, Pilishvili T, Jackson D, Facklam RR, Jorgensen JH, Schuchat A. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003; 348:1737-46.
7. Levine MM, Lagos R, Levine OS, Heitmann I, Enriquez N, Pinto ME, Alavarez AM, Wu E, Mayorga C, Reyes A. Epidemiology of invasive pneumococcal infections in infants and young children in Metropolitan Santiago, Chile, a newly industrializing country. Pediatr Infect Dis J 1998; 17:287-93.
8. Lagos R, Munoz A, Valenzuela MT, Heitmann I, Levine MM. Population-based surveillance for hospitalized and ambulatory pediatric invasive pneumococcal disease in Santiago, Chile. Pediatr Infect Dis J 2002; 21:1115-23.
9. Wenger JD, DiFabio J, Landaverde JM, Levine OS, Gaafar T. Introduction of Hib conjugate vaccines in the nonindustrialized world: Experience in four 'newly adopting' countries. Vaccine 1999; 18:736-42.
10. Lagos R, Levine OS, Avendano A, Horwitz I, Levine MM. The introduction of routine Haemophilus influenzae type b conjugate vaccine in Chile: A framework for evaluating new vaccines in newly industrializing countries. Pediatr Infect Dis J 1998; 17:S139-48.
11. Ferreccio C, Ortiz E, Astroza L, Rivera C, Clemens J, Levine MM. A population-based retrospective assessment of the disease burden resulting from invasive Haemophilus influenzae in infants and young children in Santiago, Chile. Pediatr Infect Dis J 1990; 9:488-94.
12. Clemens JD, Ferreccio C, Levine MM, Horwitz I, Rao M, Edwards K, Fritzell B. Impact of Haemophilus influenzae type b polysaccharide-tetanus protein conjugate vaccine on responses to concurrently administered diphtheria-tetanus- pertussis vaccine. JAMA 1992; 267:673-8.
13. Ferreccio C, Clemens JD, Avendano A, Horwitz I, Flores C, Avila L, Cayazzo M, Fritzell B, Cadoz M, Levine MM. The clinical and immunologic response of Chilean infants to Haemophilus influenzae type b polysaccharide-tetanus protein conjugate vaccine coadministered in the same syringe with DTP at two, four and six months of age. Pediatr Infect Dis J 1992; 10:764-71.
14. Avendaño A, Ferreccio C, Lagos R, Horwitz I, Cayazzo M, Fritzell B, Meschievitz C, Levine M. Haemophilus influenzae type b polysaccharide-tetanus protein conjugate vaccine does not depress serologic responses to diphtheria, tetanus or pertussis antigens when coadministered in the same syringe with diphtheria-tetanus-pertussis vaccine at two, four and six months of age. Pediatr Infect Dis J 1993; 12:638-43.
15. Levine OS, Ortiz E, Contreras R, Lagos R, Vial P, Misraji A, Ferreccio C, Espinoza C, Adlerstein L, Herrera P. Cost-benefit analysis for the use of Haemophilus influenzae type b conjugate vaccine in Santiago, Chile. Am J Epidemiol 1993; 137:1221-8.
16. Lagos R, Horwitz I, Toro J, San Martin O, Abrego P, Bustamante C, Wasserman SS, Levine OS, Levine MM. Large scale, postlicensure, selective vaccination of Chilean infants with PRP-T conjugate vaccine: Practicality and effectiveness in preventing invasive Haemophilus influenzae type b infections. Pediatr Infect Dis J 1996; 15:216-22.
17. In: Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH, eds. Manual of clinical microbiology. Washington, DC: ASM press, 1995.
18. UNICEF. State of the World's Children 2005. Childhood under Threat. Bellamy, C. 1-151. 2005. New York: UNICEF, 2005, (Ref Type: Report).
19. Black SB, Shinefield HR, Ling S, Hansen J, Fireman B, Spring D, Noyes J, Lewis E, Ray P, Lee J, Hackell J. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. Pediatr Infect Dis J 2002; 21:810-5.
20. American College of Emergency Physicians Clinical Policies Committee. Clinical policy for children younger than three years presenting to the emergency department with fever. Ann Emerg Med 2003; 42:530-45.
21. Baraff LJ. Editorial: Clinical policy for children younger than three years presenting to the emergency department with fever. Ann Emerg Med 2003; 42:546-9.
22. Kluger MJ. Fever, its Biology, Evolution and Function. Princeton, NJ: Princeton University Press, 1979.